Kazanowska B, Reich A, Reich M, Balcerska A, Balwierz W, Bodalski J, Dłuzniewska A, Drozyńska E, Katski K, Kijowski J, Kowalczyk J, Kurylak A, Matysiak M, Mikołajewska A, Peregut-Pogorzelski J, Sopyło B, Stencel D, Szewczyk B, Wachowiak J, Wieczorek M, Wysocki M, Chybicka A
Department of Paediatric Oncology, University of Medicine, Wrocław, Poland.
Pediatr Hematol Oncol. 2004 Jun;21(4):349-62. doi: 10.1080/08880010490440491.
Soft tissue sarcomas in children are a heterogeneous group of malignant diseases. Among these, tumors localized in the head and neck region are especially difficult to treat. While multidisciplinary care has dramatically improved the prognosis of sarcoma patients, their treatment remains uncertain because of demand on radical surgical resection of the tumor. Achieving cure without deforming or mutilating the child remains the primary goal of treatment. This study is the multicenter (nationwide, 11 Polish centers) retrospective analysis of the treatment results in children having soft tissue sarcoma in the head and neck region during the previous decade (from 1991 to 2001). Late effects of the treatment are documented in long-term survivals. Eighty-five children from 1 to 212 months of age were included. Different multimodal treatment protocols were utilized (CWS-91, SIOP-MMT-91, and CWS-96). The median observation time was 25 months. Data on long-term effects were collected in 34 long-term survivals. Complete remission was achieved in 68 (80%) patients. Primary treatment failure occurred in 13 (15.3%) patients, all of whom succumbed in disease progression. Relapse occurred in 21 (30.9%) patients primarily achieving complete remission. Second primary neoplasm occurred in 3 children. The estimated 5-year event-free survival and the 5-year total survival rates for the whole group are 0.38 and 0.55, respectively. The main late effect documented in long-term survivals were cosmetic defects in 12 (35.3%) and visual field deficit or blindness in 8 (26.5%). Despite substantial improvement of the prognosis of pediatric soft tissue sarcomas, the multimodal treatment of head and neck region tumors remains controversial. Improved long-term outcome and focusing on psychosocial difficulties raise the important and difficult problem of functional results and cosmesis. Tumors localized in the orbit carry an excellent prognosis. However, the main late sequela is vision impairment and cosmetic defect due to the therapy given many years earlier. Two other tumor localizations--the parameningeal and nonparameningeal ones--still have bad prognosis. The observations made in this study confirm that main prognostic factors are the size of the primary tumor and the tumor stage. The worst prognosis remains invasive tumor (T2-stage) with a size over 5 cm. Individually adjusted multimodal therapy, which imperatively needs to be radical, though not mutilating, might minimize the late effects. Psychosocial problems in long-term survivors need to be focused on at the national level and better support must be provided in the future, involving a team of different medical and paramedical profiles.
儿童软组织肉瘤是一组异质性的恶性疾病。其中,位于头颈部区域的肿瘤尤其难以治疗。虽然多学科治疗显著改善了肉瘤患者的预后,但由于对肿瘤进行根治性手术切除的要求,其治疗仍存在不确定性。在不使儿童变形或致残的情况下实现治愈仍然是治疗的首要目标。本研究是一项多中心(全国范围,11个波兰中心)的回顾性分析,涉及过去十年(1991年至2001年)患有头颈部软组织肉瘤的儿童的治疗结果。在长期存活者中记录了治疗的晚期效应。纳入了85名年龄在1至212个月的儿童。采用了不同的多模式治疗方案(CWS - 91、SIOP - MMT - 91和CWS - 96)。中位观察时间为25个月。在34名长期存活者中收集了关于长期效应的数据。68名(80%)患者实现了完全缓解。13名(15.3%)患者出现原发性治疗失败,所有这些患者均因疾病进展而死亡。21名(30.9%)最初实现完全缓解的患者出现复发。3名儿童发生了第二原发性肿瘤。整个组的估计5年无事件生存率和5年总生存率分别为0.38和0.55。在长期存活者中记录的主要晚期效应是12名(35.3%)患者出现美容缺陷,8名(26.5%)患者出现视野缺损或失明。尽管小儿软组织肉瘤的预后有了实质性改善,但头颈部区域肿瘤的多模式治疗仍存在争议。长期结果的改善以及对心理社会困难的关注提出了功能结果和美容方面重要且棘手的问题。位于眼眶的肿瘤预后良好。然而,主要的晚期后遗症是多年前接受治疗导致的视力损害和美容缺陷。另外两个肿瘤部位——脑膜旁和非脑膜旁部位——预后仍然很差。本研究中的观察结果证实,主要的预后因素是原发性肿瘤的大小和肿瘤分期。预后最差的仍然是大小超过5厘米的浸润性肿瘤(T2期)。个体化调整的多模式治疗,虽然必须根治但不能致残,可能会将晚期效应降至最低。长期存活者的心理社会问题需要在国家层面得到关注,并且未来必须提供更好的支持,涉及不同医学和辅助医疗专业的团队。